The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.
 
Sumanta K. Pal
Consulting or Advisory Role - Astellas Pharma; Aveo; Bristol-Myers Squibb; Eisai; Exelixis; Genentech; Ipsen; Myriad Pharmaceuticals; Novartis; Pfizer
 
Amir Mortazavi
Honoraria - Motive Medical Intelligence
Consulting or Advisory Role - Debiopharm Group; Pfizer; Seagen
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Debiopharm Group (Inst); Genentech/Roche (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst)
 
Matthew I. Milowsky
Research Funding - Amgen (Inst); Arvinas (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Incyte (Inst); Inovio Pharmaceuticals (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Seagen (Inst); Syndax (Inst)
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Mamta Parikh
Consulting or Advisory Role - Exelixis; Janssen; Janssen; Seagen
 
Yung Lyou
Consulting or Advisory Role - Pfizer/EMD Serono
 
Peng Wang
No Relationships to Disclose
 
Rahul Atul Parikh
Stock and Other Ownership Interests - Myovant Sciences (I)
Consulting or Advisory Role - Merck
Research Funding - Saladax Biomedical; Taiho Pharmaceutical
Patents, Royalties, Other Intellectual Property - Patents on DNA repair pathways in cancer. I do not receive any royalties for the same.
 
Benjamin A. Teply
Consulting or Advisory Role - AstraZeneca; Janssen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Inovio Pharmaceuticals (Inst)
Patents, Royalties, Other Intellectual Property - Receive royalties from patents related to health/medicine, held by MIT
 
Robert Dreicer
Consulting or Advisory Role - Astellas Pharma; Bayer; Eisai; EMD Serono; Infinity Pharmaceuticals; Merck; Myovant Sciences; Pfizer; Pfizer/Astellas; Propella Therapeutics; Tavanta Therapeutics; Veru
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Novartis (Inst); Seagen (Inst)
 
Hamid Emamekhoo
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Cardinal Health; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - DAVA Pharmaceuticals
 
M. Dror Michaelson
Employment - Cullinan Oncology (I); Jounce Therapeutics (I)
Stock and Other Ownership Interests - Jounce Therapeutics (I)
Honoraria - Eisai; Exelixis; Merck; Pfizer
Consulting or Advisory Role - Eisai; Exelixis; Merck; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelis (Inst); Merck (Inst); Millennium (Inst); Pfizer (Inst)
Expert Testimony - Bayer
 
Christopher J. Hoimes
Honoraria - Seagen
Consulting or Advisory Role - 2bPrecise; Bristol-Myers Squibb; Eisai; Genentech/Roche; Merck Sharp & Dohme; Prometheus; Seagen
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Genentech/Roche; Seagen
Research Funding - Merck Sharp & Dohme; Merck Sharp & Dohme (Inst)
(OPTIONAL) Uncompensated Relationships - 2bPrecise (Inst)
 
Tian Zhang
Leadership - Archimmune Therapeutics (I); Capio BioSciences (I)
Stock and Other Ownership Interests - Archimmune Therapeutics (I); Capio Biosciences (I); Nanorobotics (I)
Honoraria - Exelixis; Genentech/Roche; MJH Life Sciences; Pacific Genuity
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Exelixis; Foundation Medicine; Genentech/Roche; Janssen; Merck; Pfizer; Pharmacyclics; Sanofi; Seagen
Speakers' Bureau - Exelixis; Genentech/Roche; Genomic Health; Sanofi/Aventis
Research Funding - Acerta Pharma (Inst); Astellas Pharma; Janssen (Inst); Merck (Inst); Merrimack (Inst); Mirati Therapeutics (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst); Prochelators as Targeted Prodrugs for Prostate Cancer (Inst)
Travel, Accommodations, Expenses - Acerta Pharma; AstraZeneca; Genomic Health
 
Sandy Srinivas
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Seagen
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Merck (Inst); Seattle Genetics/Astellas (Inst)
Other Relationship - Pfizer
 
William Y. Kim
Leadership - Advanced Chemotherapy Technologies (I)
Stock and Other Ownership Interests - Abbvie; Amgen; Arvinas; Arvinas; BeiGene; Bristol-Myers Squibb; Fibrogen; FibroGen; G1 Therapeutics; Illumina; Johnson & Johnson; Kura Oncology; NantWorks; Natera; Oramed; Spectrum Pharmaceuticals; Zentalis
Honoraria - H3 Biomedicine; Takeda
Consulting or Advisory Role - Foundation Medicine; GeneCentric
Research Funding - Foundation Medicine; GeneCentric; Merck
Patents, Royalties, Other Intellectual Property - BASE47 bladder cancer subtype classifier; PurIST (Purity Independent Subtyping of Tumors) (I)
Travel, Accommodations, Expenses - H3 Biomedicine; Takeda
 
Glenn Liu
Employment - AIQ Solutions
Leadership - AIQ Solutions
Stock and Other Ownership Interests - AIQ Solutions
Consulting or Advisory Role - Exelixis; Novartis; Tricon Pharmaceuticals
Research Funding - Johnson & Johnson (Inst); Madison Vaccines, Inc.; Novartis (Inst); Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - I have patent pending titled "System and method for evaluation of disease burden" which provides a novel method to identify and quantitate treatment response. (Inst)
Travel, Accommodations, Expenses - AIQ Solutions; TRACON Pharma
 
Paul Henry Frankel
No Relationships to Disclose
 
Yuijie Cui
No Relationships to Disclose
 
Primo "Lucky" N. Lara
Consulting or Advisory Role - Calithera Biosciences (Inst); Janssen
Research Funding - Incyte (Inst); Janssen Biotech (Inst); Merck (Inst); Pharmacyclics (Inst); Taiho Pharmaceutical (Inst)